CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Revenues:
License and milestone fees	$ 24,227	$ 9,161	$ 6,393
Research and development support	7,873	4,517	7,256
Clinical materials revenue	2,843	2,679	5,656
Royalty revenue	592
Total revenues	35,535	16,357	19,305
Operating Expenses:
Research and development	87,073	69,192	63,453
General and administrative	21,471	20,422	16,040
Total operating expenses	108,544	89,614	79,493
Loss from operations	(73,009)	(73,257)	(60,188)
Investment income, net	126	66	218
Other income (expense), net	72	(128)	1,696
Net loss	(72,811)	(73,319)	(58,274)
Basic and diluted net loss per common share (in dollars per share)	$ (0.87)	$ (0.95)	$ (0.85)
Basic and diluted weighted average common shares outstanding (in shares)	84,063	76,814	68,919
Other Comprehensive Loss			(282)
Total Comprehensive Loss	$ (72,811)	$ (73,319)	$ (58,556)